MA (Cantab), PhD, EPA

rose@evolve-ip.com

Leading IP Counsel for biotech & pharmaceutical innovators

As a specialised biopharma IP Attorney, Rose provides strategic patent counsel, leads high-stakes IP due diligence, and acts as fractional in-house IP counsel for pioneering biotech companies. Her work spans the full biopharma IP life cycle, building and managing global patent portfolios, freedom-to-operate and competitive landscape analysis, life-cycle management, and the negotiation of multi-billion-dollar licensing agreements.

Technology and therapy area expertise

• Cell and gene therapy, including CAR-T, regenerative medicine, and stem cell technologies.
• In vivo cell therapy delivery technologies, including lipid nanoparticles (LNPs) and lentivectors.
• Biologics, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs).
• Oligonucleotides, RNAi, ASOs, and gene editing technologies.
• Therapy areas including neuroscience, autoimmune disease, oncology, rare disease and allergy.
• Patent strategy for products at every pipeline stage, from discovery platforms to on-market biologics.
• Expert in AI-assisted IP tools for biotech and pharma IP, including AI agents for drafting, prosecution, invention capture, searching and competitive landscape analysis.

Who Rose works with

• Biotech start-ups and scale-ups needing senior IP strategy.
• Clinical-stage and commercial-stage pharmaceutical companies.
• Founders, senior leadership, and regulatory and commercial teams.
• Investors and boards evaluating IP risk and value.
• Academic institutions, consultancies, and pharma partners on collaborations and licensing.

Selected experience

Fractional in-house IP leadership

• Cartesian Therapeutics (Nasdaq: RNAC): Serves as Lead IP Counsel for this late clinical-stage biotech pioneering RNA-based cell therapies for autoimmune diseases. Directs the build-out of internal IP processes, strategic portfolio review, competitive landscaping, and board-level IP communications.
• Strategic Financing (Cartesian): Directed the intellectual property aspects of a non-dilutive credit facility of up to $150 million from K2 HealthVentures, securing an initial $50 million tranche that extended the company’s cash runway into 2028.
• In Vivo CAR-T Licensing (Cartesian): Led IP due diligence and negotiated IP terms for a strategic licensing agreement advancing an in vivo CAR-T platform, successfully pairing targeted lipid-nanoparticle (LNP) delivery with Cartesian’s mRNA payload for autoimmune applications.
• Platform R&D Investment: Acted as the IP lead for a major pharmaceutical company’s biopharma cell therapy platform, architecting a proactive invention-capture strategy across multiple preclinical programmes to secure continued, long-term R&D investment.

High-value transactions & IP due diligence

• $2 billion+ autoimmune cell therapy deal: Led IP due diligence and supported term negotiations on the in-licensing side for a major pharmaceutical company’s collaboration and option-to-license agreement for engineered cell therapies. The deal secured $85 million upfront with over $2 billion in potential milestones and tiered royalties.
• $4.5 billion immunology & oncology collaboration: Supported IP due diligence and negotiations for a global strategic collaboration and option-to-license a partner’s multi-specific antibody platform. The transaction totalled $175 million in upfront/near-term payments, up to $4.4 billion in milestones, plus a $105 million equity investment.
• Neuroscience portfolio out-licensing: Directed IP negotiations and due diligence for the out-licensing of an entire neuroscience portfolio, covering preclinical to late-stage assets across gene therapy, small molecule, and antibody modalities.

Global patent strategy & life-cycle management

• Led global prosecution strategy for a flagship projected blockbuster biologic, securing key life-cycle-management patents across the US, Europe, China, Japan, and other major markets, extending the product’s market protection and unlocking business investment in >3 new Phase 3 trials in new indications for patients in underserved disease areas.
• Global patent term extension and SPC strategy for multiple blockbuster biologics in autoimmune and oncology.

Freedom to operate and competitive landscape analysis

• Provided critical patent infringement risk assessments and actionable, business-focused mitigation strategies for platform technologies and late-stage assets.
• Directed comprehensive intellectual property landscaping, specifically mapping IP risks and strategic white space for cell therapy platforms.

Publications & thought-leadership

• Editor of the CIPA Guide to the Patents Acts, 10th Edition (2025–present).
• Contributing author, A User’s Guide to Intellectual Property in Life Sciences (Bloomsbury Professional, 2021).
• Contributing author, Developments and Directions in Intellectual Property Law (Oxford University Press, 2023).
• “Patenting Biologic Therapeutics in the U.S. and Europe,” Landslide, American Bar Association (2022).
• Regular speaker on the epi podcast, covering EPO case law and the use of AI in the patent industry.
• Guest lecturer for the Brunel University IP law Postgrad Certificate(2025).
• IPKat contributing author.

Qualifications

• European Patent Attorney
• PhD in Immunology, University College London (UCL)
• MA (Cantab) in Natural Sciences, University of Cambridge
• Member of the European Patent Institute (epi)
• Member of the Chartered Institute of Patent Attorneys (CIPA)
• Member of the CIPA Congress Committee

Awards & industry recognition

• IP STARS: Notable Practitioner
• AstraZeneca Patent of the Year 2024, Biopharma R&D awards

Testimonials

“Rose provides rapid, expert IP strategy advice in cell and gene therapy, combining strong sector knowledge with the ability to quickly understand complex technologies. She brings technical depth, commercial awareness and a calm, solutions-focused approach, translating intricate scientific and patent issues into clear, actionable guidance.”